FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program

Loading...
Loading...

The FDA has lifted the clinical hold on Spero Therapeutics Inc's SPRO Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease.

  • The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate (NHP) toxicology study in which mortalities with inconclusive causality to treatment were observed. 
  • The FDA's decision to lift the hold follows Spero's submission of a comprehensive study report with detailed analyses from the NHP toxicology study. 
  • Related: Spero Therapeutics Stock Surges On $40M Equity Funding, SPR206 Licensing Pact With Pfizer.
  • NTM lung disease is a general term for disorders characterized by exposure to specific bacterial germs known as mycobacteria. 
  • Spero plans on engaging with the FDA in Q1 of 2022 to discuss the re-initiation of the SPR720 Phase 2 trial, with an expected study start date commencing in 2H of 2022.
  • SPR720 represents a novel antibacterial agent class that targets enzymes essential for bacterial DNA replication. 
  • Price Action: SPRO shares are down 0.86% at $15.02 during the market session on the last check Tuesday.
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...